(Source: Xencor Inc) MONROVIA, Calif., June 28, 2016 /PRNewswire/ -- Xencor, Inc. (Xencor) (NASDAQ:XNCR) announced today that it has entered into a collaboration and license agreement with Novartis to develop and commercialize novel therapeutics, including XmAb®14045 expected to begin clinical development for acute myeloid leukemia in 2016; and XmAb®13676 also expected to begin clinical development for B-cell malignancies in 2016. 'We are excited to move forward in collaboration with Novartis on the development of XmAb14045 and XmAb13676, while maintaining our rights in the U.S.,' said Bassil Dahiyat, Ph.D., president and chief executive officer of Xencor. 'This opportunity to work with and...
↧